Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
13.60
+0.82 (6.38%)
At close: Jul 25, 2025, 4:00 PM
13.60
0.00 (0.04%)
After-hours: Jul 25, 2025, 7:26 PM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 403 employees as of December 31, 2024. The number of employees decreased by 123 or -23.38% compared to the previous year.
Employees
403
Change (1Y)
-123
Growth (1Y)
-23.38%
Revenue / Employee
$113,074
Profits / Employee
-$1,304,998
Market Cap
1.41B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NTLA News
- 7 days ago - With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy' - Seeking Alpha
- 18 days ago - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewsWire
- 2 months ago - Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course - Benzinga
- 2 months ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 2 months ago - Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting - GlobeNewsWire
- 2 months ago - Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript) - Seeking Alpha
- 2 months ago - Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade) - Seeking Alpha